益气维血联合铁剂对比生血宝联合铁剂治疗贫血相关疾病的临床疗效  

Clinical efficacy comparison of Yiqiweixue combined with iron supplement and Shengshuibao combined with iron supplement in treatment of anemia-related diseases

作　　者：曹琰 于梦洋 金德奎 杨姗姗[1] 钟立胜 郑姣 张承英[1] CAO Yan;YU Mengyang;JIN Dekui;YANG Shanshan;ZHONG Lisheng;ZHENG Jiao;ZHANG Chengying(General Department,the Third Medical Center of PLA general Hospital,Beijing 100039,China)

机构地区：[1]解放军总医院第三医学中心全科医学科,北京100039

出　　处：《武警医学》2024年第11期948-951,955,共5页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的 对比益气维血片/胶囊联合铁剂与生血宝合剂/颗粒联合铁剂治疗贫血相关疾病的临床疗效。方法 选取2019-2021年全国6省市10家综合医院信息系统数据库中,接受诊疗超过1年的贫血相关疾病患者916例,根据治疗方法不同分为观察组和对照组,观察组采用益气维血片/胶囊联合铁剂>30 d(n=514),对照组采用生血宝合剂/颗粒联合铁剂>30 d(n=402),采用倾向性评分匹配(PSM)方法平衡观察组和对照组的基线特征,每组205例。有效性指标为治愈率[患者血红蛋白(Hb)恢复正常1年的累计发生率]、有效率(Hb上升>10 g/L 1年的累计发生率)、Hb恢复正常中位时间及Hb上升>10 g/L中位时间;安全性指标为肝功能ALT、AST前后变化。结果 两组治愈率均为44.39%,无统计学差异;观察组有效率明显高于对照组(67.32%vs. 54.63%,P<0.01);两组中位Hb恢复正常时间、中位Hb上升>10 g/L时间均相当,均未观察到中位复发时间。两组的ALT、AST值与用药前相比均无明显上升(P>0.05)。结论 两组治愈率、治愈和起效时间无差别,具有较好的安全性,益气维血有效率显著优于生血宝,具有临床推广价值。Objective To compare the clinical efficacy of Yiqiweixue tablets/capsules combined with iron supplements and Shengxuebao combination/granules combined with iron supplements in the treatment of anemia-related diseases.Methods A total of 916 patients with anemia-related diseases who had received treatment of Yiqiweixue(n=514)and Shengxuebao(n=402)for more than 1 year were selected from the information system database of 10 general hospitals in 6 provinces and cities across China from 2019 to 2021.Propensity score matching(PSM)method was used to balance the baseline characters of the observation and control group.After PSM,205 cases the observation group of Yiqiweixue tablets/capsules combined with iron for>30 days,while the control group of Shengxuebao combination/granules combined with iron for>30 days.The effectiveness indicators included cure rate(the cumulative incidence rate of patients whose hemoglobin(Hb)levels return to normal within one year),and efficacy rate(the cumulative incidence rate of patients whose Hb levels increase by more than 10g/L within one year),median time for Hb to return to normal and median time for Hb increase of more than 10 g/L.Safety indicators were changes of liver function ALT and AST.Results The cure rates of the two groups were 44.39%,with no statistically significant difference;the efficacy rate of the observation group was significantly higher than that of the control group(67.32%vs.54.63%,P<0.01);both the median time for Hb to return to normal and the median time for Hb to increase by more than 10 g/L were not significantly different in two groups,and no median relapse time was observed.The ALT and AST values in both groups showed no significant increase after treatment(P>0.05).Conclusions There is no difference in cure rate,time to cure and onset of actio between the 2 groups.Both treatments showed no impacts on liver function,but Yiqiweixue has significantly higher effective rate than Shengxuebao,which can be recommended for clinical use.

关 键 词：益气维血 生血宝 铁剂 贫血相关疾病 

分 类 号：R556.3[医药卫生—血液循环系统疾病]